the trelys funds  
innovation, cultivation, growth

Metabolon CEO Named One of the Most Inspiring People in Life Sciences

RESEARCH TRIANGLE PARK, NC - Metabolon, Inc., a leader in the discovery of biomarkers through the use of metabolomics, today announced its president and CEO, Dr. John Ryals, has been selected as one of the "100 Most Inspiring People in the Life Sciences Industry" by the readers of PharmaVOICE magazine. Dr. Ryals is showcased in the magazine’s August issue.

"I am honored to be recognized as an inspiring member of the life sciences community," said Dr. Ryals. "But this would have never been possible without all of the incredible people I’ve worked with over the years."

Individuals were selected based on how they have inspired and motivated those around them, their influence as a corporate leader, and how they have had a positive impact on the industry through their actions.

By educating the public on metabolomics, its benefits and importance, Dr. Ryals has quickly established Metabolon at the forefront of the biomarker industry. With more than 20 years of experience in biotechnology, Dr. Ryals brings a balance of entrepreneurial expertise and a deep background in life sciences to the company helm.

About Metabolon
Metabolon is an industry leader in the discovery of biomarkers through the use of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In conjunction with the NIH, Metabolon was recently honored as a recipient of the 2005 March of Dimes Award for Best Research in Prematurity. For additional information, visit

© the trelys funds